Leyh, C.; Heucke, N.; Schotten, C.; Büchter, M.; Bechmann, L.P.; Wichert, M.; Dechêne, A.; Herrmann, K.; Heider, D.; Sydor, S.;
et al. LiMAx Prior to Radioembolization for Hepatocellular Carcinoma as an Additional Tool for Patient Selection in Patients with Liver Cirrhosis. Cancers 2022, 14, 4584.
https://doi.org/10.3390/cancers14194584
AMA Style
Leyh C, Heucke N, Schotten C, Büchter M, Bechmann LP, Wichert M, Dechêne A, Herrmann K, Heider D, Sydor S,
et al. LiMAx Prior to Radioembolization for Hepatocellular Carcinoma as an Additional Tool for Patient Selection in Patients with Liver Cirrhosis. Cancers. 2022; 14(19):4584.
https://doi.org/10.3390/cancers14194584
Chicago/Turabian Style
Leyh, Catherine, Niklas Heucke, Clemens Schotten, Matthias Büchter, Lars P. Bechmann, Marc Wichert, Alexander Dechêne, Ken Herrmann, Dominik Heider, Svenja Sydor,
and et al. 2022. "LiMAx Prior to Radioembolization for Hepatocellular Carcinoma as an Additional Tool for Patient Selection in Patients with Liver Cirrhosis" Cancers 14, no. 19: 4584.
https://doi.org/10.3390/cancers14194584
APA Style
Leyh, C., Heucke, N., Schotten, C., Büchter, M., Bechmann, L. P., Wichert, M., Dechêne, A., Herrmann, K., Heider, D., Sydor, S., Lemmer, P., Ludwig, J. M., Pospiech, J., Theysohn, J., Damm, R., March, C., Powerski, M., Pech, M., Özcürümez, M.,
... Manka, P. P.
(2022). LiMAx Prior to Radioembolization for Hepatocellular Carcinoma as an Additional Tool for Patient Selection in Patients with Liver Cirrhosis. Cancers, 14(19), 4584.
https://doi.org/10.3390/cancers14194584
